GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Antibody
Comment: Adimanebart is an anti-muscle associated receptor tyrosine kinase (MuSK) monoclonal antibody with agonist action. It was designed to treat neuromuscular diseases, by improving impaired function at the neuromuscular junction in patients with conditions that are characterised by fatigable muscle weakness, such as congenital myasthenia, myasthenia gravis and ALS. The goal of this approach is to reduce muscle weakness and fatigability. This may be the INN for argenx's clinical candidate ARGX-119 [1].
|
| No information available. |
Summary of Clinical Use  |
| ARGX-119 is a clinical candidate for neuromuscular disorders such as amyotrophic lateral sclerosis (ALS) and congenital myasthenic syndrome. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06436742 | A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants with DOK7-Congenital Myasthenic Syndromes (CMS) | Phase 1 Interventional | argenx | ||
| NCT06441682 | A Safety and Efficacy Study of ARGX-119 in Adult Patients with Amyotrophic Lateral Sclerosis (ALS) | Phase 2 Interventional | argenx | ||
